Histopathology of human liver biopsies
View samplesHistopathology of human liver biopsies
Template
Attributes
| Name | Type | Description | PID  | Unit |
|---|---|---|---|---|
| PAT.ID* | String | Not specified | - | - |
| Diagnosis group* | Controlled Vocabulary - Diagnostic groups | Not specified | - | - |
| Age | Real number | Not specified | - | yr |
| Sex | Controlled Vocabulary - Gender | Not specified | - | - |
| Weight (kg) | Real number | Not specified | - | - |
| BMI | String | Not specified | - | - |
| Diabetes Typ II | String | Not specified | - | - |
| Surgery indication | String | Not specified | - | - |
| Histology: NAS score | Real number | Not specified | - | - |
| Histology: NAS fat | Real number | Not specified | - | - |
| Histology: NAS balloning | Real number | Not specified | - | - |
| Histology: NAS inflammation | Real number | Not specified | - | - |
| Fat | Real number | Not specified | - | % |
| Fibrosis | Real number | Not specified | - | - |
| Blood test: GGT (U/l) | Real number | Not specified | - | - |
| Blood test: AP (U/l) | Real number | Not specified | - | - |
| Blood test: total bilirubin (µmol/l) | Real number | Not specified | - | - |
| Blood test: ALT (U/l) | Real number | Not specified | - | - |
| Blood test: AST (U/l) | Real number | Not specified | - | - |
| Bile acids: primary (µmol/l) | Real number | Not specified | - | - |
| Bile acids: secondary (µmol/l) | Real number | Not specified | - | - |
| Bile acids: 2º/1º | Real number | Not specified | - | - |
| 3D reconstruction | String | Not specified | - | - |
Tags
Not specified Creators and Submitter
Views: 58
Created: 27th Jan 2022 at 20:48
Last updated: 27th Jan 2022 at 21:01
Related items
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
One of the tasks of the healthy liver is to store fat. Yet, at some stage, too much fat makes the liver sick. One critical time point occurs when a healthy fatty liver becomes inflamed and progresses to steatohepatitis, or NASH. LiSyM-Pillar I will identify what events lead to this transition. Does it occur in all parts of the liver? Which molecules indicate that it is taking place? Can the degeneration be stopped or undone - and if so, how?
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research/zones-of-the-liver
Start date: 1st Jan 2016
